Assessment of Tumor Proliferation after Anti-tumor Therapy by Thymidine Kinase 1 Activity with Nuclear Medicine Technique
Assessment of Tumor Proliferation after Anti-tumor Therapy by Thymidine Kinase 1 Activity with Nuclear Medicine Technique
批准号:
12470187
负责人:
SAKAHARA Harumi
金额:
$7.94万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2002
中文摘要
目的:3'-脱氧-3'-[^<18>F - flt]氟胸腺嘧啶(^<18>F- flt)是一种正电子发射断层扫描(PET)示踪剂,被细胞摄取并被胸腺嘧啶激酶1磷酸化,与细胞增殖密切相关。本研究的目的是评估^< 18b> F-FLT作为肿瘤增殖标志物的作用。方法:SCCVII、PANC-1、LS174T和HeLa四种细胞系在体内表现出不同的生长速度。将^<18 b> F-FLT的肿瘤摄取与移植了这些细胞的小鼠的肿瘤加倍时间进行比较。在20 Gy照射后6小时至7天,检测了x射线照射对荷瘤小鼠^<18>F-FLT、^<18> f -氟-2-脱氧-d -葡萄糖(^<18>F-FDG)、^ 3h -甲基胸腺嘧啶(^3H-Thd)、^<14> c -2-脱氧-d -葡萄糖(^<14>C-DG)摄取的影响。光动力治疗后24小时检测肿瘤对每种放射性药物的摄取情况。静脉给药1小时后测定肿瘤对放射性药物的摄取情况。结果:4个细胞系中F-FLT的摄取与倍增时间无关。x射线照射后6小时,肿瘤对^<18 b> F-FLT和^3H-Thd的摄取显著减少。然而,^<18>的F-FDG和^<14>的C-DG的吸收量直到照射后3天才减少。光动力治疗减少了治疗后24小时^<18>的F-FDG和^3H-Thd的摄取,但没有减少^<18>的F-FDG和^<14>的C-DG的摄取。结论:^<18>F-FDG比^<18>F-FDG对放射治疗或光动力治疗反应的评价更敏感。
英文摘要
Objectives : 3'-deoxy-3'-[^<18>F]fluorothymidine (^<18>F-FLT), a positron emission tomography (PET) tracer, is taken up by cells and phosphorylated by thymidine kinase 1, which is closely tied to cellular proliferation. The aim of this study was to evaluate ^<18>F-FLT as a tumor proliferation marker. Methods : Four cell lines, SCCVII, PANC-1, LS174T, and HeLa show different growth rate in vivo. Tumor uptake of ^<18>F-FLT was compared to the doubling time of tumor in mice transplanted with these cells. The effect of X-ray irradiation on the uptake of ^<18>F-FLT, ^<18>F-fluoro-2-deoxy-D-glucose (^<18>F-FDG), ^3H-methyl-thymidine (^3H-Thd), ^<14>C-2-deoxy-D-glucose (^<14>C-DG) was examined in tumor-bearing mice between 6 hrs and 7 days after 20 Gy irradiation. Tumor uptake of each radiopharmaceutical was also examined at 24 hours after photodynamic therapy. The uptake of radiopharmaceuticals in tumor was determined at 1 hour after intravenous administration. Results : There was no relation between the doubling time and uptake of ^<18>F-FLT among 4 cell lines. Tumor uptake of ^<18>F-FLT and ^3H-Thd significantly decreased at 6 hours after X-ray irradiation. The uptake of ^<18>F-FDG and ^<14>C-DG, however, did not decrease until 3 days after irradiation. Photodynamic therapy decreased the uptake of ^<18>F-FLT and ^3H-Thd but not the uptake of ^<18>F-FDG nor ^<14>C-DG at 24 hours after therapy. Conclusion : ^<18>F-FLT is more sensitive than ^<18>F-FDG for the evaluation of the response to radiation therapy or photodynamic therapy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Search for new biomarker of anti-cancer drug effect using near-infrared diffuse optical spectroscopy targeting vasculature and hypoxia
-
批准号:26282144
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$9.98万
-
财政年份:2014
-
负责人:SAKAHARA Harumi
-
依托单位:
Development of novel CT contrast agents with long retention in the vessel
-
批准号:21390343
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$6.41万
-
财政年份:2009
-
负责人:SAKAHARA Harumi
-
依托单位:
Studies on radiopharmaceuticals with mitochondria membrane potential dependent tumor accumulation
-
批准号:17390330
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$6.1万
-
财政年份:2005
-
负责人:SAKAHARA Harumi
-
依托单位:
国内基金
海外基金
登录
查看更多内容
USP43-SAFB1轴调控FLT3突变急性髓系白血病细胞对FLT3抑制剂耐药的机制研究
-
批准号:JCZRQNB202600664
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向CASP1/GSDMD通路抑制FLT3突变阳性
AML患者耗竭性γ δ T细胞焦亡的机制研
究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:金真伊
-
依托单位:
Nup98-HoxD13/Flt3-ITD协同突变诱导急性髓系细胞白血病发生分子机制
-
批准号:82570227
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2025
-
负责人:李延安
-
依托单位:
FLT3-ITD突变体诱导AML细胞逃逸巨噬细
胞吞噬作用的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:陈树钊
-
依托单位:
FLT3调控结肠癌细胞膜MHCI稳定性的机制及干预策略研究
-
批准号:D25H300004
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:丁玲
-
依托单位:
诱导自噬的FLT3/RET双靶点药物设计、合成及抗耐药性AML研究
-
批准号:82560677
-
项目类别:地区科学基金项目
-
资助金额:32.00万元
-
批准年份:2025
-
负责人:黄强
-
依托单位:
骨髓微环境VEGFC-VEGFR2信号轴介导
FLT3-ITD阳性急性髓系白血病对吉瑞替
尼耐药的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:王培鸿
-
依托单位:
工程化RGD-内皮化人脐带间充质干细胞外泌体靶向递送FLT1调控PI3K/Akt通路促进SCI后血管新生和BSCB重建
-
批准号:2025JJ60555
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:谢勇
-
依托单位:
新型小分子FLT3抑制剂STI-8591在FLT3突变急性髓系白血病中的应用及机制研究
-
批准号:MS25H080016
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:张仪
-
依托单位:
靶向CD44分子对Notch抑制剂联合TKI治疗FLT3-ITD突变AML的作用和机制研究
-
批准号:JCZRYB202500792
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位: